Yan Cheng
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Instructor
Also affiliated: National Institutes of Health (2014); University of British Columbia (2014–2015); China Pharmaceutical University (2015–2020); Okayama University (2013); University of New Mexico (2013); Anhui Medical University (2024); Chinese Academy of Sciences (2008); Medical College of Wisconsin (2019–2022); University of Utah (2013–2019); University of Arkansas Medical Center (2023); Yidu Central Hospital of Weifang (2018–2019); Optum (United States) (2015); Peking University First Hospital (2020–2022); Shanghai Institute of Optics and Fine Mechanics (2008); National Cancer Institute (2014); Second Affiliated Hospital of Anhui Medical University (2024); First Affiliated Hospital of Zhengzhou University (2021); Third Xiangya Hospital (2023); Xiangya Hospital Central South University (2023); First Hospital of Xi'an (2018); State Key Laboratory of Natural Medicine (2015–2020); Henan Normal University (2008); University of Pennsylvania (2000); Tsinghua University (2013–2025)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Yan Cheng's research focuses on understanding the biological mechanisms underlying cancer development and identifying potential therapeutic strategies. Her work investigates the role of tumor risk genes, the influence of the neural and immune components within the tumor microenvironment, and the development of novel immune-based cancer therapies. Cheng's doctoral training at China Pharmaceutical University centered on tumor biology and immunology, followed by postdoctoral research at the Medical College of Wisconsin, where she conducted basic and translational studies on multiple myeloma.
Her research interests have led to publications exploring the intersection of stress, the immune system, and cancer progression. Recent work has examined how chronic stress impacts colitis by altering gut microbiota and immune responses, and how depression can promote prostate cancer growth and metastasis through sympathetic signaling pathways. Cheng is an Instructor at the University of Arkansas for Medical Sciences, where she collaborates with researchers including Fumou Sun and Fenghuang Zhan. Her scholarly output includes over 100 publications and a h-index of 26.
Metrics
- h-index: 25
- Publications: 103
- Citations: 2,180
Positions
-
Instructor 2022–presentUniversity of Arkansas for Medical Sciences Internal Medicine ORCID
Selected Publications
-
Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma (2026)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing (2024)
-
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)
-
IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (2023)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
Collaboration Network
Top Collaborators
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 15 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 12 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 11 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 11 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 9 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 9 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
Showing 5 of 7 shared publications
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics